Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the "Inscobee Parties"), resolving all outstanding disputes arising from the APUS' December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement of Lōkahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program.

APUS' common stock is expected to resume trading on the NYSE American on Tuesday, May 5, 2026, subject to NYSE approval.